Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus

Overview of attention for article published in Circulation Reports, September 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 35 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 7,846 followers.

RT @drleonjimenez: @afcisnal @ConchiNavarroH @SantasEnrique Teneis este estudio comparativo también. De unos japoneses. https://t.co/lrzZZI…

22 Jan 2020

Reply Repost Favourite

@afcisnal @ConchiNavarroH @SantasEnrique Teneis este estudio comparativo también. De unos japoneses. https://t.co/lrzZZIvAAp Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patien

21 Jan 2020

Reply Repost Favourite

RT @drleonjimenez: Class efect or not? https://t.co/gAGXEGW587

02 Oct 2019

Reply Repost Favourite

RT @drleonjimenez: Class efect or not? https://t.co/gAGXEGW587

02 Oct 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.